Clinical Trial

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) at the putative RP2D(s) (Part 2: Dose Expansion).
Protocol Amendment History 1 change
notable Trial sites expanded: 9 -> 19 locations 2026-07-11
Trial Details
NCT Number NCT07308132
Lead Sponsor Janssen Research & Development, LLC
Conditions Lymphoma, Non-Hodgkin
Enrollment 130 participants
Start Date 2026-01-20
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-10